Table 2

Cohort characteristics at 24-month follow-up

All subjects at baseline (n=292)All subjects at follow-up (n=292)Cases at follow-up
(n=146)
Controls at follow-up
(n=146)
P1P2
Total cholesterol, mg/dL182 (154–211)164 (138–196)166 (138–199)162 (137–194)<0.001*†0.619†
HDL cholesterol, mg/dL39 (34–47)40 (34–48)39 (33–45)42 (35–52)0.290†0.033*†
LDL cholesterol, mg/dL103 (81–126)87 (70–112)92 (71–111)86 (70–115)<0.001*†0.981†
HbA1c, %8.2 (7.6–8.9)7.1 (6.4–7.8)7.0 (6.3–8.0)7.1 (6.4–7.7)<0.001*†0.350†
eGFR, mL/min89.30 (74.80–105.38)79.00 (64.20–91.00)79.90 (63.98–90.48)75.80 (64.60–94.80)<0.001*†0.527†
ACEI and/or ARB, n (%)202/292 (69)205/258 (79)106/133 (80)99/124 (80)0.009*‡1.000‡
Antiplatelet, n (%)148/289 (51)165/257 (64)86/133 (65)79/123 (64)0.001*‡0.658‡
Statin, n (%)173/290 (60)194/258 (75)105/133 (79)89/124 (72)<0.001*‡0.043*‡
  • Variables expressed as median (IQR) or n (%).

  • *P < 0.05 considered significant.

  • †Wilcoxon signed rank test for paired subjects or repeated measures within each subject.

  • ‡McNemar’s test for paired subjects or repeated measures within each subject.

  • ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; P1, comparison between baseline and follow-up for all subjects in the entire cohort; P2, comparison between matched cases and controls at follow-up.